Mary Katherine Kosowski
Adult Health · West Seneca, NYNPI 1558937441
Payments from drug & device makers
Across 120 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$453
- Lilly USA, LLC$420
- Boehringer Ingelheim$286
- Insulet Corporation$227
- Amneal Pharmaceuticals LLC$217
- Amgen$167
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 9 | $453 |
| Lilly USA, LLC | 23 | $420 |
| Boehringer Ingelheim | 15 | $286 |
| Insulet Corporation | 8 | $227 |
| Amneal Pharmaceuticals LLC | 9 | $217 |
| Amgen(2 entities) | 3 | $167 |
| Dexcom, Inc. | 7 | $146 |
| Bayer | 6 | $135 |
| AbbVie | 6 | $109 |
| Mannkind Corporation | 5 | $109 |
| Sanofi-aventis U.S. LLC | 4 | $98 |
| Tandem Diabetes Care, Inc. | 3 | $70 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| IBSA Pharma Inc. | 3 | $51 |
| Cequr Corporation | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Sequel Med Tech, LLC | 2 | $48 |
| Corcept Therapeutics | 2 | $41 |
| Pfizer | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Abbott | 1 | $24 |
| AstraZeneca | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$200
- Omnipod$125
- TEPEZZA$125
How this compares
$2,907 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $297,738 |
| TrulicityDulaglutide | 215 | $296,257 |
| MounjaroTirzepatide | 224 | $246,209 |
| JardianceEmpagliflozin | 213 | $200,616 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $81,965 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $54,268 |
| ProliaDenosumab | 30 | $51,343 |
| Humalog Kwikpen U-100Insulin Lispro | 143 | $47,477 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 245 | $39,896 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $39,853 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $39,135 |
| RybelsusSemaglutide | 20 | $34,152 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $31,988 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 94 | $21,692 |
| FarxigaDapagliflozin Propanediol | 24 | $18,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $420 | $547,795480 claims |
| Boehringer IngelheimJardiance | $286 | $200,616213 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $98 | $59,14151 claims |
| AmgenProlia | $167 | $51,34330 claims |
| AstraZenecaFarxiga | $19 | $18,03524 claims |
| AbbVieSynthroid, Armour Thyroid | $109 | $13,864133 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $217 | $9,934558 claims |
| Cequr CorporationCequr Simplicity | $50 | $7,41416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.
Other adult health in West Seneca
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.